Literature DB >> 12749861

Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore.

David G Bear1, Nathalie Fomproix, Teresa Soop, Birgitta Björkroth, Sergej Masich, Bertil Daneholt.   

Abstract

The nuclear poly(A)-binding protein, PABPN1, has been previously shown to regulate mRNA poly(A) tail length and to interact with selected proteins involved in mRNA synthesis and trafficking. To further understand the role of PABPN1 in mRNA metabolism, we used cryo-immunoelectron microscopy to determine the fate of PABPN1 at various stages in the assembly and transport of the Chironomus tentans salivary gland Balbiani ring (BR) mRNA ribonucleoprotein (mRNP) complex. PABPN1 is found on BR mRNPs within the nucleoplasm as well as on mRNPs docked at the nuclear pore. Very little PABPN1 is detected on the cytoplasmic side of the nuclear envelope, suggesting that PABPN1 is displaced from mRNPs during or shortly after passage through the nuclear pore. Surprisingly, we also find PABPN1 associated with RNA polymerase II along the chromatin axis of the BR gene. Our results suggest that PABPN1 binds to the polymerase before, at, or shortly after the start of transcription, and that the assembly of PABPN1 onto the poly(A) tail may be coupled to transcription. Furthermore, PABPN1 remains associated with the released BR mRNP until the mRNP is translocated from the nucleus to the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749861     DOI: 10.1016/s0014-4827(03)00123-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  21 in total

1.  In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1.

Authors:  João Paulo Tavanez; Patricia Calado; José Braga; Miguel Lafarga; Maria Carmo-Fonseca
Journal:  RNA       Date:  2005-04-05       Impact factor: 4.942

2.  A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.

Authors:  Aymeric Chartier; Béatrice Benoit; Martine Simonelig
Journal:  EMBO J       Date:  2006-04-27       Impact factor: 11.598

Review 3.  CBP80-promoted mRNP rearrangements during the pioneer round of translation, nonsense-mediated mRNA decay, and thereafter.

Authors:  L E Maquat; J Hwang; H Sato; Y Tang
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-03-29

4.  Evidence that poly(A) binding protein C1 binds nuclear pre-mRNA poly(A) tails.

Authors:  Nao Hosoda; Fabrice Lejeune; Lynne E Maquat
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 5.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

6.  Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.

Authors:  Aida Abu-Baker; Alex Parker; Siriram Ramalingam; Janet Laganiere; Bernard Brais; Christian Neri; Patrick Dion; Guy Rouleau
Journal:  Neurology       Date:  2018-07-13       Impact factor: 9.910

Review 7.  Determinants and implications of mRNA poly(A) tail size--does this protein make my tail look big?

Authors:  Aimee L Jalkanen; Stephen J Coleman; Jeffrey Wilusz
Journal:  Semin Cell Dev Biol       Date:  2014-06-05       Impact factor: 7.727

8.  A synthetic A tail rescues yeast nuclear accumulation of a ribozyme-terminated transcript.

Authors:  Ken Dower; Nicolas Kuperwasser; Houra Merrikh; Michael Rosbash
Journal:  RNA       Date:  2004-12       Impact factor: 4.942

9.  Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis.

Authors:  Luciano H Apponi; Sara W Leung; Kathryn R Williams; Sandro R Valentini; Anita H Corbett; Grace K Pavlath
Journal:  Hum Mol Genet       Date:  2009-12-24       Impact factor: 6.150

10.  Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1.

Authors:  João Paulo Tavanez; Rocio Bengoechea; Maria T Berciano; Miguel Lafarga; Maria Carmo-Fonseca; Francisco J Enguita
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.